CN111372929A - 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 - Google Patents
一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 Download PDFInfo
- Publication number
- CN111372929A CN111372929A CN201880075469.8A CN201880075469A CN111372929A CN 111372929 A CN111372929 A CN 111372929A CN 201880075469 A CN201880075469 A CN 201880075469A CN 111372929 A CN111372929 A CN 111372929A
- Authority
- CN
- China
- Prior art keywords
- solvent
- solvents
- crystal form
- iii
- sulfoxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法。具体而言,一种肾外髓质分泌钾通道(ROMK)抑制剂的L‑酒石酸盐的III晶型(I)及其制备方法。该III晶型具备良好的化学稳定性和晶型稳定性,并且所用结晶溶剂低毒低残留,可更好地用于临床治疗。
Description
PCT国内申请,说明书已公开。
Claims (8)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711273099 | 2017-12-06 | ||
CN2017112730992 | 2017-12-06 | ||
PCT/CN2018/119310 WO2019109935A1 (zh) | 2017-12-06 | 2018-12-05 | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111372929A true CN111372929A (zh) | 2020-07-03 |
CN111372929B CN111372929B (zh) | 2022-04-12 |
Family
ID=66750805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880075469.8A Active CN111372929B (zh) | 2017-12-06 | 2018-12-05 | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200347039A1 (zh) |
EP (1) | EP3722293A4 (zh) |
JP (1) | JP2021505602A (zh) |
KR (1) | KR20200096802A (zh) |
CN (1) | CN111372929B (zh) |
AU (1) | AU2018380171A1 (zh) |
BR (1) | BR112020011161A2 (zh) |
CA (1) | CA3084848A1 (zh) |
MX (1) | MX2020005930A (zh) |
RU (1) | RU2020122014A (zh) |
TW (1) | TWI685492B (zh) |
WO (1) | WO2019109935A1 (zh) |
ZA (1) | ZA202004017B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085210A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016091042A1 (zh) * | 2014-12-08 | 2016-06-16 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
AR092031A1 (es) * | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
MX2018014759A (es) * | 2016-06-07 | 2019-03-11 | Jiangsu Hengrui Medicine Co | Sal farmaceuticamente aceptable como inhibidor del canal de potasio medular externo renal. |
CN109879863B (zh) * | 2017-12-06 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 |
-
2018
- 2018-12-05 AU AU2018380171A patent/AU2018380171A1/en not_active Abandoned
- 2018-12-05 CA CA3084848A patent/CA3084848A1/en not_active Abandoned
- 2018-12-05 CN CN201880075469.8A patent/CN111372929B/zh active Active
- 2018-12-05 JP JP2020531026A patent/JP2021505602A/ja active Pending
- 2018-12-05 RU RU2020122014A patent/RU2020122014A/ru unknown
- 2018-12-05 MX MX2020005930A patent/MX2020005930A/es unknown
- 2018-12-05 TW TW107143628A patent/TWI685492B/zh not_active IP Right Cessation
- 2018-12-05 KR KR1020207019240A patent/KR20200096802A/ko unknown
- 2018-12-05 EP EP18886529.9A patent/EP3722293A4/en not_active Withdrawn
- 2018-12-05 WO PCT/CN2018/119310 patent/WO2019109935A1/zh unknown
- 2018-12-05 US US16/770,129 patent/US20200347039A1/en not_active Abandoned
- 2018-12-05 BR BR112020011161-9A patent/BR112020011161A2/pt not_active Application Discontinuation
-
2020
- 2020-07-01 ZA ZA2020/04017A patent/ZA202004017B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085210A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016091042A1 (zh) * | 2014-12-08 | 2016-06-16 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
Also Published As
Publication number | Publication date |
---|---|
MX2020005930A (es) | 2020-08-24 |
RU2020122014A (ru) | 2022-01-10 |
TW201925191A (zh) | 2019-07-01 |
EP3722293A1 (en) | 2020-10-14 |
CN111372929B (zh) | 2022-04-12 |
WO2019109935A1 (zh) | 2019-06-13 |
TWI685492B (zh) | 2020-02-21 |
JP2021505602A (ja) | 2021-02-18 |
ZA202004017B (en) | 2021-08-25 |
KR20200096802A (ko) | 2020-08-13 |
US20200347039A1 (en) | 2020-11-05 |
EP3722293A4 (en) | 2021-06-02 |
CA3084848A1 (en) | 2019-06-13 |
AU2018380171A1 (en) | 2020-07-09 |
BR112020011161A2 (pt) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2828636T3 (es) | Sal agonista de receptores opioides (MOR), forma cristalina I de la sal de fumarato de la misma y método de preparación de las mismas | |
JP2021530456A (ja) | 2−(3,5−ジクロロ−4−((5−イソプロピル−6−オキソ−1,6−ジヒドロピリダジン−3−イル)オキシ)フェニル)−3,5−ジオキソ−2,3,4,5−テトラヒドロ−1,2,4−トリアジン−6−カルボニトリルの固体形態 | |
US11230533B2 (en) | Crystalline salts and polymorphs of a P2X3 antagonist | |
JP5303765B2 (ja) | 結晶性イミダゾール−5−カルボン酸誘導体 | |
JP6334065B2 (ja) | キナゾリン誘導体の塩またはその結晶およびそれらの製造方法 | |
CN108779122B (zh) | 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法 | |
CN108290874B (zh) | 一种肾外髓质分泌钾通道抑制剂的可药用盐 | |
CN111372929B (zh) | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 | |
WO2018149309A1 (zh) | 4-苯基噻唑衍生物的晶型及其制备方法 | |
CN109879863B (zh) | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 | |
US20130143846A1 (en) | Polymorphic form of a calcimimetic compound | |
TWI762825B (zh) | 酪胺酸激酶抑制劑的一馬來酸鹽的晶型及其製備方法 | |
KR20150020191A (ko) | 아고멜라틴 산기 복합체와 그의 제조방법 및 용도 | |
JP6317358B2 (ja) | L‐リジンを含む(3s,3s’)4,4’‐ジスルファンジイルビス(3‐アミノブタン1‐スルホン酸)の新規結晶相 | |
WO2023160542A1 (zh) | 二肽基肽酶抑制剂化合物的盐及晶型 | |
CN109422723B (zh) | 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法 | |
US20240002337A1 (en) | Salts and solid forms of (r)-1-(5-methoxy-1h-indol-1-yl)-n,n-dimethylpropan-2-amine | |
WO2024109727A1 (zh) | 一种吡唑并杂芳基类衍生物的可药用盐的结晶形式 | |
WO2019029477A1 (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
JP2023532217A (ja) | Shp2阻害剤の結晶形、その組成物、その製造方法及び応用 | |
CN112384221A (zh) | 异喹啉酮的多晶态和非晶态形式及其使用方法 | |
WO2020072870A1 (en) | Co-crystal forms of baricitinib | |
WO2020191140A1 (en) | Co-crystal forms of selinexor | |
ES2389589T3 (es) | Sal de fumarato de 1,4-diazabiciclo[3.2.2]nonano-4-carboxilato de 4-bromefelino, sus formas cristalinas, su preparación y su utilización en terapéutica | |
JP2019116445A (ja) | スルホンアミド化合物の結晶形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40032210 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |